A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome | MicrobiomeTrials← Back to trialsNCT05419492
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2024-05-14Est. Completion: 2028-01
Enrollment target: 47 participants Locations- UCSF Benioff Children's Hospitals, San Francisco, California, United States
- Colorado Children's Hospital, Aurora, Colorado, United States
- Nicklaus Children's Hospital, Miami, Florida, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- Mott Children's Hospital, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Nationwide Children's Hospital, Columbus, Ohio, United States
- Oregon Health and Science University (OSHU), Portland, Oregon, United States
- Cook Children's Medical Center, Fort Worth, Texas, United States
- The Royal Children's Hospital, Melbourne, Australia
- Queen Elizabeth Hospital, Glasgow, United Kingdom
- Great Ormond Street Hospital, London, United Kingdom
Other microbiome trials you might be interested in
Dravet Syndrome (DS)Lennox Gastaut Syndrome (LGS)
The main aim of the study is to learn if soticlestat, when given as an add-on therapy, reduces the number of seizures in…
Phoenix, United StatesCompleted Sep 24, 2025
Focal Seizures
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut sy…
Phoenix, United StatesEst. completion Nov 29, 2027
Contact